Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy.
There is now considerable evidence that treatment of abnormalities of lipids and lipoproteins reduces the incidence of coronary heart disease (CHD). Treatment of hypertension, another major cardiovascular risk factor, has not been shown to have the same impact on CHD. Possible explanations for this are that cardiovascular risk factors may occur in combination in an individual or that therapy for hypertension has adversely affected one or several of the other risk factors for CHD, thereby offsetting the benefit gained by lowering blood pressure. This article reviews the relationship between lipids, lipoproteins, and coronary heart disease, and the impact of cholesterol lowering on CHD. The evidence that antihypertensive drugs are associated with lipid and lipoprotein abnormalities is introduced by a critical appraisal of the several studies for such evidence. Implications for the treatment of the hypertensive patient are discussed.
Feher
M D
MD
Department of Therapeutics, Charing Cross and Westminster Medical School, St. Stephen's Hospital, London, U.K.
Betteridge
D J
DJ
D000959:Antihypertensive Agents / Q000009:adverse effects*; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002784:Cholesterol / Q000097:blood; D003245:Consensus Statements as Topic; D003327:Coronary Disease / Q000097:blood*; D004232:Diuretics; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood* / Q000187:drug effects; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects; D013565:Sympatholytics / Q000494:pharmacology
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D008055:Lipids; D008074:Lipoproteins; D049993:Sodium Chloride Symporter Inhibitors; D013565:Sympatholytics; D002784:Cholesterol